Baker Bros. Advisors LP
SEC-identified person · CIK 1263508 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| vTv Therapeutics Inc. VTVT | Director | filed 2024–2026 |
| Kymera Therapeutics, Inc. KYMR | Director | filed 2024–2026 |
| Synta Pharmaceuticals Corp SNTA | Director | filed 2023–2026 |
| Beigene, Ltd. ONC | Director | filed 2016–2026 |
| Prelude Therapeutics Inc PRLD | Director | filed 2020–2026 |
| Incyte Corp INCY | Director | filed 2012–2026 |
| Denali Therapeutics Inc. DNLI | Director | filed 2025–2026 |
| Acadia Pharmaceuticals INC ACAD | Director | filed 2012–2026 |
| Kiniksa Pharmaceuticals, Ltd. KNSA | Director | filed 2018–2026 |
| Tscan Therapeutics, Inc. TCRX | Director | filed 2021–2026 |
| Replimune Group, Inc. REPL | Director | filed 2025–2026 |
| DBV Technologies S.A. DBVT | Director | filed 2021–2026 |
| Bicycle Therapeutics plc BCYC | Director | filed 2024–2026 |
| Kodiak Sciences Inc. KOD | Director | filed 2018–2025 |
| Entrada Therapeutics, Inc. TRDA | Officer | filed 2021–2025 |
| Kala Pharmaceuticals, Inc. KALA | Officer | filed 2024–2025 |
| Celcuity Inc. CELC | Officer | filed 2025–2025 |
| IGM Biosciences, Inc. IGMS | Director | filed 2019–2025 |
| Immunocore Holdings plc IMCR | Director | filed 2024–2025 |
| Sera Prognostics, INC. SERA | Officer | filed 2025–2025 |
| Neurogene Inc. NLTX | Director | filed 2015–2023 |
| Seagen Inc. SGEN | Director | filed 2012–2023 |
| Bellicum Pharmaceuticals, INC BLCM | Officer | filed 2015–2023 |
| Atreca, Inc. BCEL | Officer | filed 2019–2023 |
| Talis Biomedical Corp TLIS | Director | filed 2021–2023 |
| Spyre Therapeutics, Inc. SYRE | Director | filed 2021–2021 |
| Alexion Pharmaceuticals, INC. alxn | Director | filed 2015–2020 |
| Zymeworks Inc. ZYME | Director | filed 2020–2020 |
| Genomic Health INC GHDX | Director | filed 2012–2019 |
| Idera Pharmaceuticals, INC. IDRA | Director | filed 2014–2019 |
| Hookipa Pharma Inc. HOOK | Officer | filed 2019–2019 |
| Principia Biopharma Inc. PRNB | Officer | filed 2018–2018 |
| Invitae Corp NVTA | Officer | filed 2015–2018 |
| Mirati Therapeutics, Inc. mrtx | Officer | filed 2013–2017 |
| Rhythm Pharmaceuticals, INC. SRYTM | Officer | filed 2017–2017 |
| Biocryst Pharmaceuticals INC BCRX | Officer | filed 2012–2016 |
| Intellia Therapeutics, Inc. NTLA | Officer | filed 2016–2016 |
| Xoma Royalty Corp XOMAD | Director | filed 2012–2015 |
| Trimeris INC TRMS | Director | filed 2012–2015 |
| Intrabiotics Pharmaceuticals INC /DE RDEA | Director | filed 2012–2012 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.